Libya vs North Macedonia: Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology
Libya
0.2%
in 2024
North Macedonia
0.2%
in 2024
Libya rank
78th
North Macedonia rank
78th
Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology over time
- Libya
- North Macedonia
How they compare
Libya currently reports 0.2% against 0.2% in North Macedonia, a difference of 0.0%.
The two have swapped places 1 time across 10 shared years of data; in 2015 it was Libya ahead.
Libya ranks 78th and North Macedonia ranks 78th of 215 countries.
Libya has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Libya | North Macedonia | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 0.2% | 0.1% | 0.1% | Libya |
| 2020s | 0.2% | 0.1% | 0.1% | Libya |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher prevalence of hepatitis b surface antigen (hbsag), 2026 methodology, Libya or North Macedonia?
- Libya, at 0.2% against 0.2% in North Macedonia as of 2024.
- What is the difference in prevalence of hepatitis b surface antigen (hbsag), 2026 methodology between Libya and North Macedonia?
- 0.0%, with Libya ahead.
- How many years of comparable data are there for Libya and North Macedonia?
- 10 years are reported by both, from 2015 to 2024.
- How do Libya and North Macedonia rank globally for prevalence of hepatitis b surface antigen (hbsag), 2026 methodology?
- Libya ranks 78th and North Macedonia ranks 78th of 215 countries.
- Where does this data come from?
- United Nations Statistics Division, SDG Global Database, published as Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.